/
BRNS
$0.66-$0.04 (-5.63%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$28.6M
41M shares
52-week range
$0.51 – $2.92
6% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
ADRC
Price (6 mo)
Loading chart…
Change$-3.44
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $6.8M | $4.8M | $268.0K | $44.7M | $802.0K | $15.0M | $0 |
| Cost of revenue | $29.8M | $14.4M | $0 | $0 | $0 | $0 | $5.9M |
| Gross profit | −$23.0M | −$9.6M | $268.0K | $44.7M | $802.0K | $15.0M | −$5.9M |
| Gross margin | -336.0% | -198.4% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| R&D | $29.8M | $14.4M | $16.4M | $41.1M | $41.4M | $38.3M | $25.6M |
| Operating income | −$25.7M | −$20.0M | −$45.2M | −$4.0M | −$83.9M | −$68.0M | −$54.2M |
| EBITDA | −$22.5M | −$16.6M | −$47.9M | $5.2M | −$71.1M | −$55.4M | −$62.9M |
| Net income | −$20.7M | −$17.7M | −$50.9M | $5.3M | −$73.3M | −$61.1M | −$66.6M |
| Net margin | -302.8% | -367.3% | -18979.5% | 11.9% | -9145.5% | -408.0% | — |
| EPS (diluted) | -436.87 | -2.24 | -1.37 | 0.14 | -1.91 | -1.55 | -1.64 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $738662 | $-1.15 | $-1.15–$-1.15 | 1 |
| 2027 | $0 | $-1.15 | $-1.15–$-1.15 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.48
Price
$0.66
Implied upside
+124%
Peer comparison
Barinthus Biotherapeutics plc American Depositary Shares
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
www.barinthusbio.com- Employees
- 14
- IPO / List date
- Apr 30, 2021
- HQ
- GERMANTOWN, MD
Held by traders on TradeandTell
No one on the platform currently holds BRNS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 151,000 | $85.9K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BRNS yet.
